Access cutting-edge solid tumors treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access solid tumors specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related solid tumors treatment provided free
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). DT2216 is an anti-apoptotic protein B-cell lymphoma-extra large targeted protein degrader. It may stop the growth of tumor cells by blocking Bcl-xL, a pro
Sponsor: Children's Oncology Group
Check if you qualify for this solid tumors clinical trial in Los Angeles, CA
If you're searching for solid tumors treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.